Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Rapid Diagnostic Tests Evaluated for HIV/Syphilis

By LabMedica International staff writers
Posted on 22 Jan 2019
Sexually transmitted infections, such as human immunodeficiency virus (HIV) and syphilis, are among the major health care problems worldwide, especially in low- and middle-income countries. More...
HIV screening programs have been widely used for many years.

The introduction of rapid point-of-care tests (RDTs) that can detect both HIV and syphilis, using one single blood specimen, would be a promising tool to integrate the detection of syphilis into HIV programs and so improve the accessibility of syphilis testing and treatment.

Scientists at the Institute of Tropical Medicine (Antwerp, Belgium) and their international colleagues evaluated the laboratory performance of four dual HIV-Syphilis RDTs. All four assays were evaluated using the same characterized evaluation panel of 400 serum/plasma specimens from European, African, Asian, South American and Australian origin. The panel consisted of 200 anti-HIV antibody positive specimens, of which 100 were anti-TP (Treponema pallidum) antibody positive and 100 were anti-TP antibody negative, and 200 anti-HIV antibody negative specimens, of which 100 were anti-TP antibody positive and 100 anti-TP antibody negative.

The following dual HIV-Syphilis RDTs were evaluated simultaneously: SD Bioline HIV/Syphilis Duo; DPP HIV-Syphilis Assay; Multiplo Rapid TP/HIV Antibody Test. The evaluation of the Insti Multiplex HIV-1/HIV-2/Syphilis Antibody Test, was performed at a later time point. The SD Bioline and the DPP assay are lateral flow (immunochromatographic) RDTs while Multiplo and INSTI are RDTs based on the flow through (immunofiltration) principle.

The investigators reported that in total 400 specimens were tested with each assay, resulting in excellent sensitivities and specificities for HIV, ranging from 99.5% to 100% and from 93.5% to 99.5%, respectively. Results obtained for the Treponema pallidum antibodies were lower, with the lowest sensitivity of 73.5% for Multiplo and the highest of 87% for SD Bioline. Specificities ranged from 99% to 100%. After initial testing, 83.8% (335/400) of the results were in concordance with the Treponema pallidum antibodies reference results in all assays.

The authors concluded that the results of this laboratory evaluation suggest that combined HIV/Syphilis rapid diagnostic tests are a useful tool for the detection of both infections using the same device, and can increase the accessibility of HIV/Syphilis diagnosis for difficult to reach populations in the world. The tests under investigation could further improve in accuracy, especially in the detection of treponemal antibodies, but are promising enough to be introduced into screening programs. The study was published on January 3, 2019, in the journal BMC Infectious Diseases.

Related Links:
Institute of Tropical Medicine


New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Clinical Informatics Platform
CLARION™
New
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.